Single-use systems (SUS) integrity assurance is crucial to drug development, providing a foundation for sterility assurance, contamination control, and patient safety. While it must be aligned with regulatory expectations for control, supporting evidence, and documentation, these do not remain static across development. As programs progress from early development to commercialization and post-approval, expectations for justification, validation, and lifecycle control increase. In this context, SUS integrity refers to maintaining the intended sterile pathway and system performance throughout use.
A common challenge is applying a consistent strategy throughout development, then encountering issues when regulators expect different levels of control at different stages. This can lead to rework, delays, and inspection challenges.
Cytiva supports drug product manufacturers through regulatory services and phase-appropriate regulatory documentation that align system selection, risk justification, validation planning, and lifecycle control with development stage. This helps teams make confident decisions earlier and avoid misalignment later.
As shown in Fig. 1, single-use systems can involve multiple connection points, flow paths, and operator interactions, highlighting why integrity must be clearly defined, controlled, and documented from the earliest stages of development.'
Fig 1. Operator handling critical connections in a drug product filtration system.
What regulators look for across the stages of pharmaceutical development
Regulators assess whether drug product strategy and controls are appropriate for the stage of development, with expectations increasing as product and process maturity increase. The level of evidence and control expected should be justified based on product, process, development stage, and patient risk.
In the context of SUS integrity assurance, regulators evaluate whether:
- Integrity risks are identified and controlled appropriately
- Decisions are supported by appropriate evidence (e.g., supplier data vs internal validation)
- The overall strategy reflects process maturity and clinical risk
- These expectations evolve across development as activities, control strategies, and documentation become more structured and robust.
Why phase-appropriate strategy matters for SUS integrity
A phase-appropriate strategy aligns integrity assurance, documentation, and risk management with the stage of development. Early stages rely more on supplier data and scientific justification, while later stages require validated control strategies and lifecycle management.
For SUS integrity and sterility assurance, this progression is critical. Integrity should be managed as a lifecycle risk, evolving from system selection and justification through validation and ongoing control.
Misalignment can result in unnecessary testing early on, insufficient control later, and may lead to delays or regulatory challenges.
The evolution of integrity strategy, evidence, and control across the lifecycle can be summarized:
|
Development stage |
Integrity strategy |
Primary evidence |
Control approach |
|
Early development |
Initial risk identification and system suitability |
Supplier data (e.g., sterilization, extractables) and targeted checks |
Risk-based justification; limited formal control |
|
Clinical development |
Process-specific integrity controls implemented and refined |
Structured risk assessments and qualification data under process conditions |
Defined controls with increasing consistency and reproducibility |
|
Late stage and commercial |
Finalized integrity strategy with validated methods |
Validation data, defined acceptance criteria, and full traceability |
Robust, validated control strategies aligned to commercial manufacturing |
|
Post-approval and lifecycle |
Lifecycle management of integrity strategy |
Ongoing monitoring, trending, and change control documentation |
Sustained control through formal lifecycle and change management |
Early development (pre-investigational new drug [IND]/pre-clinical trial application [CTA]/scientific advice): what regulators expect
Early development focuses on preparing for first-in-human studies, including defining chemistry, manufacturing, and controls (CMC) strategy and early regulatory planning.
At this stage, developers should:
- Select fit-for-purpose systems
- Define sterile boundaries
- Identify key integrity risks
- Justify a risk-based approach using supplier data
The emphasis is on scientific justification rather than validated control.
Regulatory interactions (e.g., scientific advice, pre-IND) focus on whether the proposed approach is reasonable and appropriately justified.
Development documentation typically includes:
- Supplier data (e.g., sterilization, extractables)
- High-level risk assessments
- Early qualification records
Cytiva supports this stage by providing quality and regulatory support documentation and early-stage guidance (e.g., regulatory support files [RSF], validation guides [VG]), enabling developers to justify decisions without applying late-stage validation expectations too early.
Clinical development (IND/CTA, Phase I–II): increasing focus on control, consistency, and risk
Clinical development involves active studies while continuing to refine drug product manufacturing processes.
At this stage, developers should:
- Translate early strategy into defined process controls
- Implement documented integrity measures
- Perform formal risk assessments
- Demonstrate reproducible performance under clinical conditions
Regulatory interactions focus on how initial quality control strategies are implemented and refined into consistent, well-controlled approaches.
Key activities include:
- Defining sterile boundaries
- Identifying critical integrity points
- Applying process-specific controls
- Qualifying systems under intended conditions
- Documentation becomes more structured, including:
- Formal risk assessments
- Documented control strategies
- Qualification records
Cytiva supports this transition by combining supplier data, validation guidance, and change visibility (e.g., RSF, VG, validation support files [VSF], change control notifications [CCN]), helping developers move from justification to structured control.
Late stage and commercial development (Phase III/commercial readiness): inspection readiness and lifecycle thinking
Late-stage development focuses on demonstrating that processes are fully defined, validated, and reproducible at commercial scale.
At this stage, developers should:
- Finalize integrity strategy
- Confirm critical integrity points and acceptance criteria
- Validate testing methods where required
- Integrate controls into process validation and contamination control strategy
Regulatory interactions focus on completeness, consistency, and scientific justification of development data, ensuring readiness for regulatory review and inspection.
Key activities include:
- Executing process validation
- Finalizing control strategies
- Preparing audit-ready documentation
- Ensuring alignment between documentation and operations
- Documentation must:
- Demonstrate validated control
- Provide evidence of traceability and performance
- Reflect a fully defined, inspection-ready manufacturing strategy
Cytiva supports this stage through structured documentation (e.g., VSF, VG, RSF) that enables validation, traceability, and inspection readiness.
Post-approval and lifecycle: change management, comparability, and ongoing compliance
After approval, the focus shifts to maintaining control and managing change throughout the product lifecycle.
At this stage, developers should:
- Maintain validated integrity strategies
- Monitor system performance
- Trend relevant data
- Manage changes through formal lifecycle processes
Regulatory expectations focus on continued control, change management, and demonstrating that changes do not adversely impact product quality.
Key activities include:
- Ongoing monitoring and trending
- Change impact assessment
- Maintaining inspection readiness
- Supporting continuous improvement
Documentation supports:
- Change control and traceability
- Regulatory impact assessments
- Ongoing performance verification
Cytiva supports lifecycle management through change notifications (CCN) and supporting documentation (RSF, VSF, VG), enabling effective evaluation of change impact and continued compliance.
Common misalignments across the drug product lifecycle
Misalignment occurs when integrity strategies do not evolve with development stage. Common examples include:
- Applying late-stage validation too early
- Relying on supplier data too late
- Delaying definition of sterile boundaries
- Treating integrity as a one-time test rather than a lifecycle control
- Failing to maintain change awareness during development
- Inadequate post-approval change impact assessment
Avoiding these issues requires aligning control, documentation, and risk management with development stage.
Key takeaways
Building a robust drug product strategy requires:
- Applying a lifecycle-based approach: Align strategy, documentation, and risk with development stage
- Using structured documentation: Support evolving expectations with appropriate evidence
- Translating expectations into practice: Ensure control strategies are practical, reproducible, and inspection-ready
- Maintaining change awareness: Proactively manage supplier and system changes
Phase-appropriate SUS integrity assurance drives pharma regulatory compliance
SUS integrity assurance cannot remain static across the regulatory lifecycle. As development progresses, expectations for control, documentation, and justification increase.
Aligning integrity strategy with development stage reduces rework, strengthens regulatory justification, and supports efficient progression from early development through commercial manufacture and lifecycle management. This can help teams scale with greater confidence, avoid delays, and maintain control as products and processes evolve.